Actively Recruiting
The Preventive Effect of Shenfu Injection on Myocardial Dysfunction in Sepsis
Led by First Affiliated Hospital of Wannan Medical College · Updated on 2025-03-27
440
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
F
First Affiliated Hospital of Wannan Medical College
Lead Sponsor
S
Suzhou Municipal Hospital of Anhui Province
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study focuses on improving heart function in patients with life-threatening blood infections (septic shock). When the body fights severe infections, the heart sometimes struggles to pump blood effectively, which can lead to dangerous complications. Current treatments like intravenous fluids and blood pressure medications have limitations in protecting heart function. This multicenter clinical trial aims to evaluate whether adding Shenfu Injection - a traditional Chinese medicine preparation widely used to enhance cardiac function in cardiovascular diseases - to standard therapies can: 1. Prevent myocardial dysfunction during septic shock 2. Accelerate cardiac recovery if complications occur 3. Improve overall survival and clinical outcomes The randomized controlled design will compare therapeutic effects between two groups: one receiving standard septic shock treatment alone, and the other receiving standard treatment combined with Shenfu Injection.
CONDITIONS
Official Title
The Preventive Effect of Shenfu Injection on Myocardial Dysfunction in Sepsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients clinically diagnosed with septic shock meeting Sepsis 3.0 diagnostic criteria
- Age 18 years or older
You will not qualify if you...
- Pregnant or breastfeeding women
- History of allergies or known hypersensitivity to Ginseng and Aconite Injection or its components
- Severe underlying diseases affecting prognosis, including uncontrolled metastatic tumors, blood disorders, cachexia, active bleeding, severe malnutrition, or HIV
- Severe cardiac conditions within the last three months such as acute unstable myocardial infarction, dilated cardiomyopathy, acute coronary syndrome, valvular heart disease, or congestive heart failure (NYHA Class IV)
- Cardiac surgery or related procedures within the last three months
- Use of Ginseng and Aconite Injection for less than 48 hours
- Patients expected to die within 48 hours
- Patients deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)
Wuhu, Anhui, China, 241001
Actively Recruiting
Research Team
Q
Qiancheng Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here